LALPATHLAB2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2022-04-01 2023-03-31 2023-01-24 INR Millions Third quarter Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2022-10-01 2022-12-31 Unaudited Consolidated 4894000000.00 105000000.00 4999000000.00 1109000000.00 0.00 0.00 963000000.00 91000000.00 379000000.00 1692000000.00 4234000000.00 765000000.00 0.00 765000000.00 229000000.00 0.00 229000000.00 0.00 536000000.00 0.00 0.00 0.00 0.00 536000000.00 12000000.00 548000000.00 528000000.00 8000000.00 540000000.00 8000000.00 834000000.00 10 6.37 6.35 0.00 0.00 6.37 6.35 i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 2 February, 2023. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2022 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 Interim Financial Reporting ( Ind AS 34 ), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. During the period ended 31 December 2022, the Parent Company has issued 7,000 equity shares of face value of INR 10 each on exercise of employee stock options. Subsequent to the period ended 31 December 2022, the Parent Company has issued 2,000 equity shares of face value of INR 10 each on exercise of employee stock options. v. The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 28 July, 2022 which has been paid on 24 August, 2022. The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2022. The same was approved by the shareholders in the Annual General Meeting held on 30 June, 2022 which has been paid on 13 July, 2022. Due to size constraint, we have not pasted complete note to statement of financial results. Please refer pdf file for complete notes to the statement of Financial Results for the quarter and nine months ended December 31, 2022. Single segment 2022-04-01 2022-12-31 Unaudited Consolidated 15259000000.00 275000000.00 15534000000.00 3413000000.00 0.00 0.00 2840000000.00 285000000.00 1126000000.00 5263000000.00 12927000000.00 2607000000.00 0.00 2607000000.00 849000000.00 -84000000.00 765000000.00 0.00 1842000000.00 0.00 0.00 0.00 0.00 1842000000.00 36000000.00 1878000000.00 1822000000.00 20000000.00 1858000000.00 20000000.00 834000000.00 10 22.00 21.92 0.00 0.00 22.00 21.92 Fees to collection centers/channel partners 693000000.00 Other Expenses 999000000.00 Fees to collection centers/channel partners 2132000000.00 Other Expenses 3131000000.00